IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,178 Shares of Intellia Therapeutics, Inc. $NTLA

IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 177.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,387 shares of the company’s stock after buying an additional 188,178 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.28% of Intellia Therapeutics worth $2,761,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Whipplewood Advisors LLC raised its position in shares of Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after buying an additional 3,447 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after buying an additional 1,655 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Intellia Therapeutics by 76.7% during the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after buying an additional 2,264 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Intellia Therapeutics by 846.4% during the first quarter. Quantbot Technologies LP now owns 6,663 shares of the company’s stock valued at $47,000 after buying an additional 5,959 shares during the last quarter. Finally, 49 Wealth Management LLC bought a new stake in shares of Intellia Therapeutics during the first quarter valued at approximately $74,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $14.79 on Tuesday. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -3.15 and a beta of 2.37. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.25. The firm has a 50-day moving average of $16.90 and a two-hundred day moving average of $12.18.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same quarter in the prior year, the company earned ($1.52) EPS. The business’s revenue was up 104.3% compared to the same quarter last year. Research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NTLA. JMP Securities upgraded shares of Intellia Therapeutics from a “market perform” rating to a “market outperform” rating and set a $33.00 price objective on the stock in a research report on Monday, October 6th. Bank of America cut their target price on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a report on Monday. HC Wainwright cut their target price on shares of Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Monday. Wells Fargo & Company reissued an “overweight” rating and issued a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Wednesday, October 8th. Thirteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.05.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was bought at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares in the company, valued at $1,350,970.79. This represents a 288.24% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Michael P. Dube sold 1,871 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.10% of the stock is owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.